

Resource Summary Report

Generated by [RRID](#) on Jul 30, 2026

PerCP/Cyanine5.5 anti-mouse CD3

RRID:AB_1595597

Type: Antibody

Proper Citation

(BioLegend Cat# 100217, RRID:AB_1595597)

Antibody Information

URL: http://antibodyregistry.org/AB_1595597

Proper Citation: (BioLegend Cat# 100217, RRID:AB_1595597)

Target Antigen: CD3

Host Organism: rat

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: PerCP/Cyanine5.5 anti-mouse CD3

Description: This monoclonal targets CD3

Target Organism: mouse

Clone ID: Clone 17A2

Antibody ID: AB_1595597

Vendor: BioLegend

Catalog Number: 100217

Alternative Catalog Numbers: 100218

Record Creation Time: 20260218T231842+0000

Record Last Update: 20260225T233903+0000

Ratings and Alerts

No rating or validation information has been found for PerCP/Cyanine5.5 anti-mouse CD3.

No alerts have been found for PerCP/Cyanine5.5 anti-mouse CD3.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 26 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#).

Zhu D, et al. (2025) Enhanced viability and functional maturity of iPSC-derived islet organoids by collagen-VI-enriched ECM scaffolds. *Cell stem cell*, 32(4), 547.

Xu B, et al. (2025) Fatty acids modulate the colorectal cancer immune microenvironment via regulating the interaction and transactivation of PPAR α and P53. *Cell reports*, 44(12), 116623.

Elder AM, et al. (2025) Semaphorin7A and PD-L1 cooperatively drive immunosuppression during mammary involution and breast cancer. *Cell reports*, 44(5), 115676.

Wu Z, et al. (2025) Control of Inflammatory Response by Tissue Microenvironment. *bioRxiv* : the preprint server for biology.

Cho HS, et al. (2025) Structure of gut microbial glycolipid modulates host inflammatory response. *Cell*.

Newsome RC, et al. (2025) Microbial-derived immunostimulatory small molecule augments anti-PD-1 therapy in lung cancer. *Cell reports. Medicine*, 102519.

Gerrick ER, et al. (2024) Metabolic diversity in commensal protists regulates intestinal immunity and trans-kingdom competition. *Cell*, 187(1), 62.

Zhou C, et al. (2024) Anti-tumor efficacy of HRS-4642 and its potential combination with proteasome inhibition in KRAS G12D-mutant cancer. *Cancer cell*, 42(7), 1286.

Knorr DA, et al. (2024) Fc γ RIIB Is an Immune Checkpoint Limiting the Activity of Treg-Targeting Antibodies in the Tumor Microenvironment. *Cancer immunology research*, 12(3), 322.

Bowman RL, et al. (2024) In vivo models of subclonal oncogenesis and dependency in hematopoietic malignancy. *Cancer cell*, 42(11), 1955.

Hurrell BP, et al. (2024) Piezo1 channels restrain ILC2s and regulate the development of airway hyperreactivity. *The Journal of experimental medicine*, 221(5).

Zhang S, et al. (2023) Gut microecology may be involved in pathogenesis of Hashimoto's thyroiditis by reducing production of hydrogen sulfide. *The Journal of clinical endocrinology and metabolism*.

Cui K, et al. (2023) Restraint of IFN- γ expression through a distal silencer CNS-28 for tissue homeostasis. *Immunity*, 56(5), 944.

Chen D, et al. (2023) CTLA-4 blockade induces a microglia-Th1 cell partnership that stimulates microglia phagocytosis and anti-tumor function in glioblastoma. *Immunity*, 56(9), 2086.

Xu F, et al. (2023) Prostate cancer cell-derived exosomal IL-8 fosters immune evasion by disturbing glucolipid metabolism of CD8⁺ T cell. *Cell reports*, 42(11), 113424.

Gawish R, et al. (2022) ACE2 is the critical in vivo receptor for SARS-CoV-2 in a novel COVID-19 mouse model with TNF- α and IFN- γ -driven immunopathology. *eLife*, 11.

Masle-Farquhar E, et al. (2022) STAT3 gain-of-function mutations connect leukemia with autoimmune disease by pathological NKG2Dhi CD8⁺ T cell dysregulation and accumulation. *Immunity*, 55(12), 2386.

Kaczanowska S, et al. (2021) Genetically engineered myeloid cells rebalance the core immune suppression program in metastasis. *Cell*, 184(8), 2033.

Di Pilato M, et al. (2021) CXCR6 positions cytotoxic T cells to receive critical survival signals in the tumor microenvironment. *Cell*, 184(17), 4512.

Si J, et al. (2020) Hematopoietic Progenitor Kinase1 (HPK1) Mediates T Cell Dysfunction and Is a Druggable Target for T Cell-Based Immunotherapies. *Cancer cell*, 38(4), 551.